Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, today announced a $12.75 million Series A funding round, led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to over $15.6 million. Founded in 2022, the company has exceeded $1 million in revenue commitments, with clients ranging from early-stage biotechs to large, established biopharmaceutical companies.

Ganymede is the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries. Its Lab-as-Code technology integrates physical lab instruments, apps, data pipelines, and third-party partners like CROs and CDMOs together in a single cloud data layer. Ganymede accelerates time to innovation by giving scientists the ability to automate the world around them using cloud-controlled data flows.